Standout Papers

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy 2017 2026 2020 2023 934
  1. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy (2017)
    Ryuma Tokunaga, Wu Zhang et al. Cancer Treatment Reviews

Immediate Impact

2 by Nobel laureates 5 from Science/Nature 61 standout
Sub-graph 1 of 22

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
2024 Standout
2 intermediate papers

Works of Shivani Soni being referenced

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy
2018
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
2017 Standout

Author Peers

Author Last Decade Papers Cites
Shivani Soni 1003 276 339 885 804 110 3.1k
Shengnan Yu 1306 141 453 981 796 77 3.6k
Lü Chen 623 152 434 1781 427 147 4.1k
Peng Liu 1018 203 351 1287 1064 170 3.8k
Carolina Constantin 704 137 430 911 567 120 3.2k
Hong Li 802 246 1026 2345 375 156 4.2k
Zhe Zhang 574 119 322 973 526 130 2.4k
Ying Dong 839 108 379 1475 242 68 3.4k
Jie Cheng 758 128 969 2016 357 159 3.7k
Lihui Han 458 220 570 2489 1145 90 4.6k
Claudia Schmidt 810 114 142 1263 414 83 3.8k

All Works

Loading papers...

Rankless by CCL
2026